DelveInsight’s “Chronic Kidney Disease Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Chronic Kidney Disease, historical and forecasted epidemiology as well as the Chronic Kidney Disease market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Chronic Kidney Disease market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Chronic Kidney Disease Market Forecast
Some of the key facts of the Chronic Kidney Disease Market Report:
- The Chronic Kidney Disease market size was valued USD 4,934 Million in 2022 and is anticipated to grow with a significant CAGR during the study period (2019-2032)
- According to DelveInsight's estimate, there will be roughly 77 million instances of CKD overall in the 7MM by 2022, with about 40 million of those cases occurring in the US. During the projected era (2023-2032), it is expected that these cases will rise
- In the US, there are currently an estimated 35% of diagnosed instances of CKD, and during the research period (2019–2032), it is anticipated that this number would rise
- Diagnosed cases of Chronic Kidney Disease affected 7.8 million men and 8.3 million women in 2022, and this number is expected to rise over the course of the prediction period
- In the EU4 and the UK in 2022, there were almost 1.1 million anemia-specific cases, 2.2 million hyperparathyroidism-specific cases, and 1.4 million cases of metabolic acidosis-specific Chronic Kidney Disease (CKD)
- Key Chronic Kidney Disease Companies: ProKidney, ReataPharmaceuti cals, Inc., Novo Nordisk A/S, Boehringer Ingelheim, KBP Biosciences, Astellas Pharma Inc, Roxadustat, Parexel, Mitsubishi Tanabe Pharma, Pfizer, Novotech, Vifor Pharma, Takeda, CinCor Pharma, Galderma R&D, Abbott, Akebia Therapeutics, Amgen, and others
- Key Chronic Kidney Disease Therapies: Renal Autologous Cell Therapy (REACT), Bardoxolonemethy, Ziltivekimab, Semaglutide, JARDIANCE, KBP-5074, Roxadustat, AZD5718, rHuEPO, AST-120, IV Iron, efepoetin alfa, FCM (Ferric carboxymaltose), Epoetin, CIN-107, Nemolizumab, paricalcitol, Vadadustat, Cinacalcet, and others
- The Chronic Kidney Disease epidemiology based on gender analyzed that in the US the prevalence of Chronic Kidney Disease is higher in females than males
- The Chronic Kidney Disease market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Chronic Kidney Disease pipeline products will significantly revolutionize the Chronic Kidney Disease market dynamics.
Chronic Kidney Disease Overview
Chronic kidney disease (CKD), according to NIDDK, is characterised by damaged kidneys that are unable to filter blood as they should. CKD is defined as structural or functional abnormalities of the kidneys that have an impact on health and have been present for more than three months.
Get a Free sample for the Chronic Kidney Disease Market Report
https://www.delveinsight.com/report-store/chronic-kidney-disease-chronic-renal-failure-market
Chronic Kidney Disease Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Chronic Kidney Disease Epidemiology Segmentation:
The Chronic Kidney Disease market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:
- Total Prevalence of Chronic Kidney Disease
- Prevalent Cases of Chronic Kidney Disease by severity
- Gender-specific Prevalence of Chronic Kidney Disease
- Diagnosed Cases of Episodic and Chronic Chronic Kidney Disease
Download the report to understand which factors are driving Chronic Kidney Disease epidemiology trends @ Chronic Kidney Disease Epidemiology Forecast
Chronic Kidney Disease Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Chronic Kidney Disease market or expected to get launched during the study period. The analysis covers Chronic Kidney Disease market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Chronic Kidney Disease Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Chronic Kidney Disease Therapies and Key Companies
- Renal Autologous Cell Therapy (REACT): ProKidney
- Bardoxolonemethy: ReataPharmaceuti cals, Inc.
- Ziltivekimab: Novo Nordisk A/S
- Semaglutide: Novo Nordisk A/S
- JARDIANCE: Boehringer Ingelheim
- KBP-5074: KBP Biosciences
- Roxadustat: Astellas Pharma Inc
- AZD5718: Roxadustat
- rHuEPO: Parexel
- AST-120: Mitsubishi Tanabe Pharma
- IV Iron: Pfizer
- efepoetin alfa: Novotech
- FCM (Ferric carboxymaltose): Vifor Pharma
- Epoetin: Takeda
- CIN-107: CinCor Pharma
- Nemolizumab: Galderma R&D
- paricalcitol: Abbott
- Vadadustat: Akebia Therapeutics
- Cinacalcet: Amgen
Discover more about therapies set to grab major Chronic Kidney Disease market share @ Chronic Kidney Disease Treatment Market
Chronic Kidney Disease Market Strengths
- The emerging treatment pipeline is robustly humongous attributing to novel MoAs
Chronic Kidney Disease Market Opportunities
- The rising data on CKD and its risk factors is expected to add significantly to the patient pool
Scope of the Chronic Kidney Disease Market Report
- Study Period: 2019–2032
- Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
- Key Chronic Kidney Disease Companies: ProKidney, ReataPharmaceuti cals, Inc., Novo Nordisk A/S, Boehringer Ingelheim, KBP Biosciences, Astellas Pharma Inc, Roxadustat, Parexel, Mitsubishi Tanabe Pharma, Pfizer, Novotech, Vifor Pharma, Takeda, CinCor Pharma, Galderma R&D, Abbott, Akebia Therapeutics, Amgen, and others
- Key Chronic Kidney Disease Therapies: Renal Autologous Cell Therapy (REACT), Bardoxolonemethy, Ziltivekimab, Semaglutide, JARDIANCE, KBP-5074, Roxadustat, AZD5718, rHuEPO, AST-120, IV Iron, efepoetin alfa, FCM (Ferric carboxymaltose), Epoetin, CIN-107, Nemolizumab, paricalcitol, Vadadustat, Cinacalcet, and others
- Chronic Kidney Disease Therapeutic Assessment: Chronic Kidney Disease current marketed and Chronic Kidney Disease emerging therapies
- Chronic Kidney Disease Market Dynamics: Chronic Kidney Disease market drivers and Chronic Kidney Disease market barriers
- Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
- Chronic Kidney Disease Unmet Needs, KOL’s views, Analyst’s views, Chronic Kidney Disease Market Access and Reimbursement
To know more about Chronic Kidney Disease companies working in the treatment market, visit @ Chronic Kidney Disease Clinical Trials and Therapeutic Assessment
Table of Contents
1. Chronic Kidney Disease Market Report Introduction
2. Executive Summary for Chronic Kidney Disease
3. SWOT analysis of Chronic Kidney Disease
4. Chronic Kidney Disease Patient Share (%) Overview at a Glance
5. Chronic Kidney Disease Market Overview at a Glance
6. Chronic Kidney Disease Disease Background and Overview
7. Chronic Kidney Disease Epidemiology and Patient Population
8. Country-Specific Patient Population of Chronic Kidney Disease
9. Chronic Kidney Disease Current Treatment and Medical Practices
10. Chronic Kidney Disease Unmet Needs
11. Chronic Kidney Disease Emerging Therapies
12. Chronic Kidney Disease Market Outlook
13. Country-Wise Chronic Kidney Disease Market Analysis (2019–2032)
14. Chronic Kidney Disease Market Access and Reimbursement of Therapies
15. Chronic Kidney Disease Market Drivers
16. Chronic Kidney Disease Market Barriers
17. Chronic Kidney Disease Appendix
18. Chronic Kidney Disease Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services
